Andy is a Medicinal Chemist with over 25 years of experience working in major pharma (Sanofi-Aventis, AZ). He has experience across all discovery phases, having supported five candidates into the clinic. He is the author and inventor of over 55 publications and patents. Andy has been working full-time with o2h Ventures since 2013, leading the scientific evaluation of investments and providing scientific support on key projects within the portfolio. He is currently the CSO of Opal Oncology and had previously served as CSO for two o2h early-stage collaborations.